The combination of an EZH2 inhibitor with a PD-L1 blocker was suggested after examination of an SCLC cohort in which most patients displayed a stark lack of PD-L1 expression while harboring higher levels of EZH244. The gene discussed is EZH2; the disease is small cell lung carcinoma.